NCOA1 anticorps (pTyr418)

N° du produit ABIN318122

L’anticorps Lapin Polyclonal anti-NCOA1 a été validé pour WB et IHC (p). Il convient pour détecter NCOA1 dans des échantillons de Humain, Souris et Rat.

Aperçu rapide pour NCOA1 anticorps (pTyr418) (ABIN318122)

Antigène: NCOA1 (Nuclear Receptor Coactivator 1 (NCOA1))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NCOA1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-NCOA1 anticorps

Épitope: pTyr418

Specificité: This antibody detects endogenous levels of SRC pTyr418 protein.

Purification: Affinity Chromatography using epitope-specific immunogen.

Information d'application

Indications d'application: ELISA: 1/20000-1/40000. Western Blot: 1/500-1/1000. Immunohistochemistry: 1/50-1/200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH ~7.2 containing 0.05 % Sodium Azide as preservative.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur NCOA1

Antigène: NCOA1 (Nuclear Receptor Coactivator 1 (NCOA1))

Autre désignation: SRC1

Sujet: The SRC gene is similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. Mutations in this gene could be involved in the malignant progression of colon cancer. The protein product is pp60vsrc, a cytoplasmic protein with tyrosine-specific protein kinase activity that associates with the cytoplasmic face of the plasma membrane. The protein consists of three domains, an N-terminal SH3 domain, a central SH2 domain and a tyrosine kinase domain. The SH2 and SH3 domains cooperate in the auto-inhibition of the kinase domain. c-Src is phosphorylated on an inhibitory tyrosine near the c-terminus of the protein. This produces a binding site for the SH2 domain which, when bound, facilitates binding of the SH3 domain to a low affinity polyproline site within the linker between the SH2 domain and the kinase domain. Binding of the SH3 domain results in misalignment of residues within the kinase domain's active site inactivating the enzyme. This allows for multiple mechanism for c-Src activation: dephosphorylation of the C-terminal tyrosine by a protein tyrosine phosphatase, binding of the SH2 domain by a competitive phospho-tyrosine residue, as seen in the case of c-Src binding to focal adhesion kinase, or competitive binding of a polyproline binding site to the SH3 domain, as seen in the case of the HIV NEF protein.Synonyms: Proto-oncogene c-Src, Proto-oncogene tyrosine-protein kinase Src, c-Src, pp60c-src

Poids moléculaire: approx. 60 kDa

ID gène: 6714

NCBI Accession: NP_005408

UniProt: P12931

Pathways: Intracellular Steroid Hormone Receptor Signaling Pathway, Nuclear Hormone Receptor Binding, Chromatin Binding, Regulation of Lipid Metabolism by PPARalpha